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Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an
inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish
patients with PC and 760 healthy men, we evaluated the associations of CRP genotypes and haplotypes with total PC risk and PC
progression, using prostate-specific antigen (PSA) as a marker of metastatic disease. Although the haplotype frequencies were similar
in patients and controls, an association between haplotype ACCCA and patients’ PSA levels was found. The carriers more often had
a high PSA than non-carriers (P¼0.0002) and the SNP rs2794521 A-allele and rs1800947 C-allele carriers had a higher PSA than
non-carriers (P¼0.009 and P¼0.0004, respectively). A trend for a younger age at diagnosis was found among the carriers of
ACCCA (P¼0.07) and the rs1800947 C-allele (P¼0.06), as well as a trend for the latter to have more likely metastases (P¼0.06),
but not after Bonferroni correction (a¼0.00208). This is the first study to suggest association between PSA and CRP variants in PC
and, therefore, further studies are warranted. CRP alleles previously found to protect against increased CRP levels are now suggested
to be associated with metastatic PC, indicated by elevated PSA.
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Prostate cancer (PC) is the most common non-cutaneous cancer
in men in western countries. Prostate cancer is a very hetero-
geneous and complex disease, and its pathogenesis involves
both hereditary and environmental components. The histological
and clinical heterogeneity of PC is also reflected at the molecular
level; it is still unknown if PC is caused by a single series of
genetic events or whether PC is really composed of genetically
distinct subgroups. Growing evidence points towards the role of
chronic inflammatory states in PC (de Visser et al, 2006; De Marzo
et al, 2007). Chronic inflammation has long been linked to cancers
such as stomach, liver and large intestine cancers, for which the
causative role of inflammation has already been established (Ames
et al, 1995; Lu et al, 2006). In PC, inflammation is probably
triggered by infectious agents or exposure to environmental
factors, such as dietary-derived toxins or a combination of both.
Other potential initiating events of inflammation include urine
reflux, physical and chemical trauma and oestrogens. The recently
proposed hypothesis for PC carcinogenesis suggests that the
prostate is first damaged by these triggering factors that then lead
to the development of chronic inflammation and regenerative ‘risk
lesions’, that is proliferative inflammatory atrophy (PIA)
(De Marzo et al, 1999). Furthermore, damage to the epithelia
may cause a loss of tolerance to normal prostatic antigens,
resulting in a self-perpetuating autoimmune reaction. Histologi-
cally, most prostatic lesions containing either acute or chronic
inflammatory infiltrates are associated with atrophic epithelium or
focal epithelial atrophy (De Marzo et al, 1999). Morphologically,
transitions from atrophic epithelium to adenocarcinoma and
transitions from PIA to high-grade prostatic intraepithelial
neoplasia have been observed (De Marzo et al, 1999; Putzi and
De Marzo, 2000; Montironi et al, 2002).
C-reactive protein (CRP) is a widely used marker for the
detection of inflammation and tissue damage. It is part of the
soluble innate immunity system and belongs to the family of
pattern-recognition molecules, which are able to bind foreign
molecules for phagocytosis. After binding to a ligand, CRP binds to
Fcg receptors on phagocytic cells and thus mediates ligand
elimination from the body. C-reactive protein is also able to
activate the complement cascade by binding C1q. The known
ligands for CRP are chromatin, histones, fibronectin, laminin and
small nuclear ribonuclear particles (Stein et al, 2000). The ability of
CRP to bind nuclear antigens, as well as its ability to increase the
clearance of host apoptotic and necrotic cells, has led to the theory
that CRP may prevent autoimmunity (Szalai, 2004). According to a
recent systemic review of the association between serum CRP and
cancer, CRP concentrations are usually higher in patients with
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scancer than in healthy controls, but the association seems to be
site specific (Heikkila et al, 2007). The existing literature also
suggests that CRP could hold a function as a prognostic marker
for metastasised or androgen-independent PC (Beer et al,
2008; Nakashima et al, 2008), although the overall serum
CRP concentrations of patients with PC seem not to be increased
compared to those of healthy controls (Platz et al, 2004;
Siemes et al, 2006; Trichopoulos et al, 2006; Heikkila et al, 2007,
2008).
Inflammation is a very complex process involving hundreds of
genes. Therefore, many genes in the inflammatory pathways may
contribute to the development of PC and are logical candidates for
genetic determinants of PC risk (Sun et al, 2007). Indeed, several
genes of innate immunity have already been associated with PC,
such as the ribonuclease L (RNASEL) (Carpten et al, 2002),
macrophage scavenger receptor 1 (MSR1)( X uet al, 2002),
members of the toll-like receptor (TLR) family (Zheng et al,
2004), macrophage inhibitory cytokine-1 (MIC-1) (Lindmark et al,
2004) and interleukin-1 receptor antagonist (IL1RN) (Lindmark
et al, 2005). The CRP gene, which is located at chromosome site
1q23, an area previously linked to PC (Smith et al, 1996), consists
of two exons and an intervening intron and is 2.5kbp in length.
Despite the suggested function for CRP as a prognostic marker,
the significance of inherited CRP variation in PC has not been
well studied. This prompted us to evaluate the possible function
of CRP in advanced PC, as well as to find potential functional
CRP SNPs relevant to PC. Here, we report an association study
of CRP genotypes and haplotypes (haplotype composed of
SNPs rs2794521, rs3091244, rs1800947, rs1130864 and rs1205)
to evaluate the relationship between PC progression and the
innate immunity gene CRP using samples from the Finnish
population.
MATERIALS AND METHODS
Patients with PC and controls
DNA samples were taken from 739 consecutive patients with PC
diagnosed between the years 2000 and 2003 and treated in the
Pirkanmaa Hospital District Area, Finland. The detailed collection
of the patients have been described elsewhere (Schleutker et al,
2000). In brief, the patients were primarily referred to the
Department of Urology in Tampere University Hospital based on
their symptoms. The clinical characteristics collected include age
at diagnosis, PSA at diagnosis, tumour-metastasis stage and
Gleason score. For pathological analyses biopsy samples were
used primarily, but if the patient underwent radical prostatectomy
and the specimen was histologically different form the original
biopsy sample it was used instead. For the association analysis, the
patients were divided into two subgroups based on their tumour
Gleason score: o7 and 47. The lower group included tumours
with a Gleason score of 7, pattern 3þ4 and the upper group were
those with a Gleason score of 7, pattern 4þ3. Serum PSA levels
were measured by the DELFIA (PerkinElmer, Wallac, Turku,
Finland) method. Because only 306 men underwent a bone scan to
evaluate the presence of metastases at diagnosis and of these 61
were diagnosed with metastases, PSA was used as a surrogate
marker for PC stage. Thus, PSA concentration was analysed both
as a continuous variable and as a categorical variable in three PSA
categories: below 20ngml
 1, between 20 and 100ngml
 1 and
greater than 100ngml
 1. These categories were selected because
patients with PC with a PSA over 20ngml
 1 are considered high-
risk patients compared to patients with a PSA below 20ngml
 1,
and patients with a PSA over 100ngml
 1 harbour a very high risk
of bone metastatic disease. The patients were classified as not
having metastases only if a bone scan had been performed and no
metastases found (n¼245).
The controls were 760 anonymous healthy male blood
donors with an age range of 18–65 years and were from the
Helsinki, Tampere or Turku areas. The blood samples were
collected by the blood centre of the Finnish Red Cross, Finland.
Both the patients and controls were of same ethnic origin (Finnish
Caucasians), and were gathered from the same region with a
relatively homogenous population structure (the western Finns, i.e.
the early settlement region) and without any statistically proven
genetic drift event. Previously, no significant differences in allele
frequency have been detected between our control sets, so they
have been considered homogenous and combined into one set
(Baffoe-Bonnie et al, 2005; Seppala et al, 2007). Written informed
consent was obtained from all the patients and the research
protocols were approved by the ethical committee of the Tampere
University Hospital.
SNP selection, genotyping and haplotyping
DNA samples, from 10ml of peripheral blood, were prepared using
the Wizard Genomic DNA Purification Kit (Promega Corporation,
Madison, WI, USA), according to the instructions of the
manufacturer. TagSNPs, a set of informative common CRP
SNPs, were chosen based on earlier publications of CRP SNPs or
on CRP SNPs deposited in the HapMap database using SNPtagger
(de Bakker et al, 2005). The tagSNPs were referenced in dbSNP
with the following accession numbers:  717 (rs2794521),  286
(rs3091244), þ1059 (rs1800947), þ1444 (rs1130864) and þ1846
(rs1205). The DNA samples were genotyped using the fluorogenic
50 nuclease assay in combination with specific TaqMan MGB
probes using the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). For SNP þ1059, a
commercially available kit was used (Assay-On-Demand,
C_177490; Applied Biosystems) with standard conditions. For
SNPs  717, þ1444 and þ1846, the nucleotide sequences of the
primers and allele-specific probes, labelled with reporter dyes,
were designed from sequences deposited in the GenBank database
using the Assay-by-Design tool and were synthesised by Applied
Biosystems. SNP  286 was genotyped as previously described
(Carlson et al, 2005), except that the A-allele detecting probe had a
final concentration of 0.6mM and no betaine was used. The PCRs
with no-template controls were performed in 384-well plates in a
total volume of 5ml in accordance with the manufacturer’s
standard protocol. The end-point reading of the fluorescence was
measured using the allelic discrimination analysis module,
resulting in a clear identification of three (six for SNP  286)
genotypes.
The haplotype estimation was carried out using the PHASE
v2.0.2 programme, which is based on a Bayesian statistical method
for reconstructing haplotypes from population genotype data, and
lists the most probable haplotypes for each individual (Stephens
and Scheet, 2005).
Statistical analysis
Statistical analysis was performed using STATISTICA 6.1 (StatSoft
Inc., Tulsa, OK, USA). Comparison of haplotype frequencies
between patients and controls was carried out by Fisher’s exact
test. Genotype and haplotype association with demographic,
clinical and pathological features of the disease was tested with
Mann–Whitney U-test, Pearson’s w
2-test and Fisher’s exact test.
The Bonferroni correction was applied to adjust the significance
level in multiple comparisons. The genotype and haplotype
associations with features of PC were regarded as statistically
significant if the obtained two-tailed P-value was less than
a¼0.00208 (a-level 0.05 divided by the number of tested
haplotypes (n¼4) multiplied by the number of end points
(n¼6); 0.05/(4 6)¼0.00208).
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sRESULTS
Patient characteristics, genotype and haplotype
frequencies
Characteristics of the 739 patients with PC are described in Table 1.
The genotype frequencies of all SNPs were in Hardy–Weinberg
equilibrium, except for SNP  286 in controls (P¼0.03). There
were no differences in the genotype frequencies of any SNP
between the patients and controls ( 717, P¼0.07;  286, P¼0.60;
þ1059, P¼0.48; þ1444, P¼0.25 and þ1846, P¼0.32) and the
frequencies were similar to those previously published in young
healthy Finnish individuals (data not shown) (Eklund et al, 2008).
Table 2 shows the haplotype frequencies for patients and
controls. Of the 739 patients and 760 controls included in the
haplotype estimation procedure, the programme yielded reliable
results for 728 (98.5%) patients and 744 (97.9%) controls, which
were subsequently used in haplotype analyses. The 5 SNPs formed
12 haplotypes in patients with PC and 9 in controls. No differences
in the haplotype frequencies between the cases and controls were
observed (Table 2), except for haplotypes ATGCA (n¼8,
P¼0.037) and GCCCG (n¼9, P¼0.002). However, due to the
very low frequency of these particular haplotypes, the results of the
hypothesis testing were prone to being affected by even small
variations in the data, leaving open the possibility for positive
findings by chance.
Haplotype and individual SNP associations
We analysed whether the carrier status of the four common
haplotypes (frequency 45%) was associated with the clinico-
pathological features of the patients with PC: PSA levels (Table 3),
T stage, M stage, Gleason score and age at diagnosis (online
Supplementary Table 4).
Although PSA acts as a continuous variable in PC, we wanted to
scrutinise the distribution of CRP haplotype frequencies among
different PSA concentrations and, thus, compared three categories.
The categories for PSA were selected based upon previous findings
that patients with PSA greater than 20ngml
 1 have a high risk and
patients with PSA greater than100ngml
 1 have a very high risk of
bone metastatic disease compared to those with PSA less than
20ngml
 1 (Oesterling, 1991; Rana et al, 1992). Prostate-specific
antigen greater than 100ngml
 1 has been found to be the single
most important indicator of metastatic disease, with a predictive
value of 100% (Rana et al, 1992), whereas the negative predictive
value of PSA less than 20ngml
 1 has been found to be about 99%
(Oesterling, 1991). In our patient group, less than half (41.6%;
n¼306) of the patients underwent a bone scan; of these, only 8.3%
(n¼61) were found to have metastases. For the patients with rare
haplotypes, statistical tests on association between metastasis and
rare haplotypes were significantly underpowered, and we had to
employ an alternative method of analysis, that is categorical PSA
analysis with the assumption that patients with PSA greater than
100ngml
 1 have a greater risk of bone metastatic disease.
We found that carriers of haplotype ACCCA were significantly
more likely to have PSA values over 100ngml
 1 at the time of
diagnosis than the ACCCA non-carriers (P¼0.0002, Table 3).
There was also a trend for these carriers to be younger at the time
of diagnosis and to have metastases more often (P¼0.07 and
P¼0.12, respectively; Supplementary Table 4), but these trends
were negligible after the Bonferroni correction (a¼0.00208). Also,
carriers of the haplotype GCGCG were more likely to have PSA
values over 20ngml
 1 than the non-carriers (P¼0.03, Table 3),
but this result was not significant after the Bonferroni correction.
The other haplotypes did not associate with any of the studied
clinicopathological features.
The CRPþ1059G4C silent base substitution in exon two was
associated with PSA levels. Carriers of the minor allele C were
more likely to have high PSA levels over 100ngml
 1 than were GG
homozygotes (P¼0.0004, Table 3). The carriers were also more
likely to have metastases and have a lower age at diagnosis
(P¼0.06 for both, online Supplementary Table 5), but the result
was not significant after the Bonferroni correction. Other SNPs
also had some significant associations with PSA or Gleason score,
but not after the Bonferroni correction. The promoter region SNP
 717 was associated with PSA levels so that the carriers of the
major allele A had higher PSA levels than the non-carriers in linear
analysis (9.1 vs 6.4ngml
 1, P¼0.009, Table 3). The other
promoter region SNP, the three-allelic CRP  286, was associated
with Gleason score; the carriers of the major allele C more often
had a Gleason score under 7 than the non-carriers (P¼0.03;
Supplementary Table 7), showing a possible protective effect for
this allele. The individual effects of the CRP SNPs on the
clinicopathological features of PC are shown in online supplement
tables (online Supplementary Tables 5–7). No statistically
significant associations were found for SNPs þ1444 and þ1846
(data not shown).
Table 1 Demographic data of patients with prostate cancer
Clinical/pathological category n (%)
Age at diagnosis
Mean±s.d. 68.3±8.7
Stage
T stage
T1–T2 (organ-confined) 547 (74.3)
T3–T4 (extracapsular) 189 (25.7)
M stage
0 (no metastasis) 245 (33.3)
1 (metastasis) 61 (8.3)
Prostate-specific antigen
o20ngml
 1 584 (79.8)
X20, p100ngml
 1 100 (13.7)
4100ngml
 1 48 (6.6)
Grade
Gleason score
a
o7 487 (69.8)
47 211 (30.2)
ao7 includes Gleason score 7 with pattern 3+4, and 47 includes Gleason score 7
with pattern 4+3.
Table 2 The CRP haplotype frequencies in patients with PC and in
controls
Patients with PC Controls
Haplotype n Frequency n Frequency P-value
a
1. ATGTG 519 0.356 553 0.372 0.400
2. ACGCA 417 0.286 431 0.290 0.871
3. GCGCG 335 0.230 305 0.205 0.108
4. ACCCA 78 0.054 95 0.064 0.241
5. AAGCG 66 0.045 82 0.055 0.238
6. ACGCG 15 0.010 18 0.012 0.727
7. GCCCG 9 0.006 0 0 0.002
8. ATGCA 7 0.005 1 0.001 0.037
9. ACGTG 4 0.003 1 0.001 0.213
10. GTGCG 3 0.002 0 0 0.121
11. AACCG 2 0.001 0 0 0.245
12. ATGCG 1 0.001 2 0.001 1.0
n (total) 1456 1488
The frequency calculations are based on the number of chromosomes.
aFisher’s exact
test.
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Chronic inflammation/chronic inflammatory states, triggered by
infectious agents or other environmental factors, have been
suggested to underlie about 20% of all human cancers in adults
(Ames et al, 1995; Coussens and Werb, 2002). Emerging evidence
has also pointed to a possible function for inflammation in the
pathogenesis of PC and recently a function for CRP as a prognostic
marker in PC has been suggested (Beer et al, 2008; Nakashima
et al, 2008). Here, we evaluated the function of an innate immunity
inflammatory candidate gene, CRP, in PC risk and in the clinical
characteristics of the disease by genotyping and haplotyping five
tagging CRP SNPs,  717,  286, þ1059, þ1444 and þ1846, and
sought for possible functional CRP SNPs by means of association
analysis.
Our results showed that the genotype and haplotype frequencies
were similar in patients and controls, except for the very rare
haplotypes, GCCCG (n¼9) and ATGCA (n¼8). Due to very low
frequency, type I error cannot be totally excluded. However, even
larger populations should be tested before totally rejecting the
possibility that there are, in fact, undetected differences between
patients and controls in the most common haplotypes, although
none were found in our study.
Our results showed an association between CRP haplotypes/
genotypes and patients’ PSA levels. The fourth most common CRP
haplotype, ACCCA, was associated with high PSA level in the
categorical analysis, but not in the continuous variable analysis,
which suggests that the association is non-linear in nature. In the
categorical analysis, we found that the carriers of the haplotype
ACCCA more often had PSA levels over 100ngml
 1 when
compared to the non-carriers (P¼0.0002), and the result remained
unchanged after Bonferroni correction for multiple comparisons
(a¼0.00208). However, we did not find that there was a
significantly higher proportion of the ACCCAþ carriers with
metastatic disease compared to non-carriers when analysing bone-
scan-verified patients (P¼0.12). However, as mentioned, the
number of patients with verified metastases was very low.
Moreover, two of the SNP alleles embedded in the ACCCA
haplotype,  717 allele A and þ1059 allele C, were also
individually associated with high PSA levels, but that result did
not remain significant after the conservative Bonferroni correc-
tion. Furthermore, in our study, the tendency of þ1059 C-allele
carriers to have metastases more often and to be younger at the
time of diagnosis when compared to GG homozygotes (P¼0.06 for
both; Supplementary Table 5) points to a function for CRP
haplotype/genotype in actual tumour growth and disease progres-
sion, but this result was also not significant after Bonferroni
correction. Taken together, we found some evidence pointing
towards an association between ACCCA haplotype and metastatic
disease, but further studies should scrutinise this connection
before any solid conclusions can be made.
The haplotype ACCCA and some of its alleles have previously
been associated with low CRP levels in Finns (Eklund et al, 2008)
as well as in other populations, (Carlson et al, 2005; Miller et al,
2005; Crawford et al, 2006; Suk Danik et al, 2006) although not all
of the SNPs of the haplotypes used in these studies were exactly the
same. According to a recent meta-analysis with well-adjusted CRP
values, systemic CRP concentrations seem not to be associated
with PC as such (Heikkila et al, 2007). However, two recent studies
suggested that circulating CRP could hold a function as a
prognostic marker for metastasised or androgen-independent PC
(Beer et al, 2008; Nakashima et al, 2008), contradicting our results.
In our study, we did not put much weight on circulating CRP
because of the problem that CRP is heavily confounded by
demographic, metabolic and socioeconomic factors, not to
mention acute infections, everyday traumas, given therapies etc.
Genetic variation, on the other hand, represents a consistent
inherited factor in CRP determination throughout life, free of
confounding. Even though elevated CRP could be associated with
some forms of PC in the above-mentioned studies, the reason for
this association might not be causal but due to confounding. This
is the reason we decided to relay on inherited variation in CRP as a
measure of lifetime exposure to either low or high levels (low/high-
exposing alleles determined in before hand in young, healthy
adults with careful adjustment for confounding factors).
Why would then a CRP haplotype previously associated with low
CRP now associated with increased PSA levels and a possible
increased risk of having metastases?
It is possible that an impaired defence mechanism, perhaps in
the form of locally reduced CRP response in the tumour, could
result in excess cellular fragments and prolonged inflammation in
the tumour because CRP cannot function sufficiently to remove all
cellular debris and/or apoptotic cells in the prostatic lesions. If we
consider early prostate neoplasia progression, where repeated
bouts of injury and cell death to the prostate epithelium occur as a
result of the action of inflammatory cells in response to pathogens
or autoimmune disease (phagocytic cells at inflammatory sites
generate reactive oxygen and nitrogen species, which damage cells
Table 3 Patients’ PSA levels according to CRP haplotype/genotype carrier status
PSA categorical (ngml
 1)
Genetic variable PSA median (ngml
 1) P-value
a o20 X20 p100 4100 P-value
a
ATGTG+ 8.9 (0.5–15720) 0.78 332 (79.4) 61 (14.6) 25 (6.0) 0.67
ATGTG  8.8 (0.5–8992) 243 (80.4) 38 (12.6) 21 (7.0)
ACGCA+ 8.8 (0.8–8992) 0.43 284 (80.0) 50 (14.1) 21 (5.9) 0.86
ACGCA  8.9 (0.5–15720) 291 (79.7) 49 (13.4) 25 (6.8)
GCGCG+ 8.9 (0.5–15720) 0.88 226 (77.7) 51 (17.5) 14 (4.8) 0.03
GCGCG  8.8 (0.5–8992) 349 (81.4) 14 (4.8) 32 (7.4)
ACCCA+ 8.5 (2.3–1750) 0.65 59 (81.9) 2 (2.8) 11 (15.3) 0.0002
ACCCA  8.9 (0.5–15720) 516 (79.6) 97 (15.0) 35 (5.4)
+1059 GG 9.1 (0.50–15720) 0.67 513 (79.4) 97 (15.0) 36 (5.6) 0.0004
+1059 GC+CC 8.6 (2.3–2200) 68 (81.9) 3 (3.6) 12 (14.5)
 717 AA+AG 9.1 (0.5–15720) 0.009 546 (79.4) 97 (14.1) 45 (6.5) 0.44
 717 GG 6.4 (1.5–5959) 36 (85.7) 3 (7.1) 3 (7.1)
 286 CC+CT+CA 8.8 (0.5–8992) 0.34 434 (78.6) 82 (14.9) 36 (6.5) 0.59
 286 TT+TA 8.6 (0.5–1272) 91 (82.7) 14 (12.7) 5 (4.5)
CRP haplotype is based on SNPs  717A4G,  286C4T4A, +1059G4C, +1444C4T and +1846G4A. GCGCG+ ¼carrier of haplotype GCGCG. GCGCG ¼ non-
carrier of haplotype GCGCG.
aThe Bonferroni-corrected significance level a is 0.05/(6 4)¼0.00208, that is the significance level a¼0.05 is divided by the number of end
points (6) multiplied by the number of tested haplotypes (4).
CRP haplotype and prostate cancer
CM Eklund et al
1849
British Journal of Cancer (2009) 100(12), 1846–1851 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sand the genome) or from direct injury from circulating carcino-
gens/toxins in the urine, the injury caused to the epithelium
triggers a restorative epithelial cell proliferation to replace the
damaged cells (Coussens and Werb, 2002; De Marzo et al, 2007).
The morphological and biological manifestations of this injury are
focal atrophy or PIA, an increase in proliferation and a massive
increase in epithelial cells possessing a phenotype intermediate
between basal cells and mature luminal cells (De Marzo et al, 1999;
Nelson et al, 2003; van Leenders et al, 2003). In this situation,
inadequate removal of cellular debris and/or apoptotic cells by
CRP and phagocytic cells could further increase inflammation or
even result in a self-perpetuating autoimmune reaction. This
would further increase inflammation and the presence of immune
cells and cytokines, leading to a vicious circle of increasing
infiltration of immune cells and inflammation, that is chronic
inflammation. All of these phases show an important connection
between inflammatory processes and induction of growth of pre-
neoplastic and neoplastic lesions in the prostate. In the prostatic
tissue, local CRP concentration in the microenvironment, instead
of the systemic CRP, could be more important in the resolution of
the inflammatory response because the ‘high’ CRP producers (by
genotype) are more capable of resolving the reaction and thus have
an advantage compared to subjects with ‘low’ CRP producers.
Monocytes and T cells have been shown to produce CRP in vitro
(Haider et al, 2006), and at least epithelial cells of the respiratory
tract are capable of CRP expression and secretion (Gould and
Weiser, 2001). If local inflammation resolution is dysregulated, the
cellular response to the pattern of chronic inflammation changes,
such that macrophages and other inflammatory cells generate a
great amount of growth factors, cytokines and reactive oxygen
species that may cause DNA damage and predispose the patient to
neoplasia.
Before our analysis, only one association study between CRP and
PC was reported. In the paper by Siemes et al (2006), an
association was sought between PC and three CRP 30 untranslated
region SNPs, þ1444, þ1846 and þ2911, but no association was
found. However, in the same study, a positive association between
þ1846 AA homozygotes and risk of lung cancer was observed (OR
2.6; 95% CI 1.6–4.4). In another study of elderly people, an
association between CRP haplotype B, bearing the þ1846 A-allele,
and cancer-related death was found, but the cancer cases were not
analysed separately according to site (Hindorff et al, 2008). This
allele A is also part of the high-PSA-associated ACCCA haplotype
in our study. Limitations of our study included the use of
anonymous blood bank controls, in which only sex and age range
are known. The controls were relatively young and a small fraction
of them will probably be affected with PC at a later age (cumulative
crude probability up to 84 years of age is 8.5% according to
Finnish Cancer Registry), which might attenuate the effects seen in
the study. However, control blood samples were collected from the
same geographic regions as the cases (all Finnish Caucasians) and
no significant differences in allele frequency have been detected
among our control sets. Significant differences were neither found
between blood donors and healthy young Finnish non-blood
donors. Therefore, they provide an unbiased survey of population
genotype frequencies.
In summary, the data presented point to a possible function of
reduced local CRP response in metastatic PC aetiology. The
possession of the CRP haplotype ACCCA, associated previously
with low CRP concentration and now with high PSA levels, could
be taken into consideration as a part of patient prognosis in PC.
However, further studies of the function of CRP in prostate
carcinogenesis are warranted, using even larger study groups from
other populations, before any solid conclusions about the function
of CRP genetics in PC are made.
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